Exodus Point Capital Management, LP Amylyx Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$18.08 - $23.45 $1.11 Million - $1.44 Million	61,532 Added 11.99%	574,623 $10.5 Million
Q2 2023 Aug 10, 2023	BUY	$20.98 - $31.42 $2.5 Million - $3.74 Million	119,187 Added 30.26%	513,091 $11.1 Million
Q1 2023 May 11, 2023	BUY	$27.71 - $40.93 $5.26 Million - $7.78 Million	189,967 Added 93.15%	393,904 $11.6 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $4.22 Million - $5.56 Million	141,718 Added 227.77%	203,937 $7.54 Million
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $792,432 - $1.43 Million	46,206 Added 288.55%	62,219 $1.75 Million
Q2 2022 Aug 19, 2022	BUY	$6.85 - $19.93 $109,689 - $319,139	16,013 New	16,013 $308,000

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.